Hongming Wei, Lu Zhan, Xinhuang Lv, Yan Lin, Jie Zheng, Wenwen Yang, Jiaming Liu, Jing Sun, Songfang Chen
{"title":"肠道共生菌Parabacteroides distasonis通过调节肠道微生物群-肠-脑轴对急性缺血性中风伴高尿酸血症患者的神经保护作用","authors":"Hongming Wei, Lu Zhan, Xinhuang Lv, Yan Lin, Jie Zheng, Wenwen Yang, Jiaming Liu, Jing Sun, Songfang Chen","doi":"10.1186/s12967-024-05800-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperuricemia is considered as an independent risk factor for acute ischemic stroke (AIS), and some AIS patients are accompanied by an increase in serum uric acid. Recent studies have highlighted the important role of gut microbiota in both hyperuricemia and AIS, but there is little available data on the relationship between gut microbiota and the pathogenesis of AIS with hyperuricemia (HAS).</p><p><strong>Methods: </strong>Here we profiled the gut microbiota composition in 63 HAS patients and 269 non-HAS patients through 16s rRNA sequencing. Male rat with hyperuricemia were subjected to middle cerebral artery occlusion (MCAO) to establish HAS model and were then treated with Parabacteroides distasonis. Subsequently, the neurological deficit, pathological damages and blood-brain barrier disruption were evaluated. Moreover, the levels of ROS, inflammatory cytokines, NF-𝜿B pathway related protein, and vascular density markers were determined.</p><p><strong>Results: </strong>There were significant differences of gut microbiota composition between HAS patients and non-HAS patients, and a significant decrease in the abundance of Parabacteroides in HAS patients compared to non-HAS patients. Animal experiments showed that supplementation with P. distasonis increased beneficial commensal bacteria, significantly improved neurological deficits, pathological damages and BBB disruption, as well as reduced the level of serum uric acid in HAS rats. We further demonstrated that P. distasonis treatment decreased ROS level and increased SOD2 level, thereby reducing oxidative stress. Meanwhile, P. distasonis effectively inhibited NF-𝜿B signal pathway and reduced the production of inflammatory cytokines, including TNF-α and IL-1β, alleviating the inflammatory response. Notably, P. distasonis treatment increased the levels of vascular density markers including cluster of differentiation 31 (CD31) and alpha-smooth muscle actin (α-SMA), ameliorating vascular damage in HAS rats.</p><p><strong>Conclusions: </strong>Together, these findings highlighted the important role of P. distasonis in the pathogenesis of HAS, and its mechanism was involved in the regulation of gut microbiota-gut-brain axis, which implied a novel strategy against HAS.</p>","PeriodicalId":17458,"journal":{"name":"Journal of Translational Medicine","volume":null,"pages":null},"PeriodicalIF":6.1000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539330/pdf/","citationCount":"0","resultStr":"{\"title\":\"Gut commensal Parabacteroides distasonis exerts neuroprotective effects in acute ischemic stroke with hyperuricemia via regulating gut microbiota-gut-brain axis.\",\"authors\":\"Hongming Wei, Lu Zhan, Xinhuang Lv, Yan Lin, Jie Zheng, Wenwen Yang, Jiaming Liu, Jing Sun, Songfang Chen\",\"doi\":\"10.1186/s12967-024-05800-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hyperuricemia is considered as an independent risk factor for acute ischemic stroke (AIS), and some AIS patients are accompanied by an increase in serum uric acid. Recent studies have highlighted the important role of gut microbiota in both hyperuricemia and AIS, but there is little available data on the relationship between gut microbiota and the pathogenesis of AIS with hyperuricemia (HAS).</p><p><strong>Methods: </strong>Here we profiled the gut microbiota composition in 63 HAS patients and 269 non-HAS patients through 16s rRNA sequencing. Male rat with hyperuricemia were subjected to middle cerebral artery occlusion (MCAO) to establish HAS model and were then treated with Parabacteroides distasonis. Subsequently, the neurological deficit, pathological damages and blood-brain barrier disruption were evaluated. Moreover, the levels of ROS, inflammatory cytokines, NF-𝜿B pathway related protein, and vascular density markers were determined.</p><p><strong>Results: </strong>There were significant differences of gut microbiota composition between HAS patients and non-HAS patients, and a significant decrease in the abundance of Parabacteroides in HAS patients compared to non-HAS patients. Animal experiments showed that supplementation with P. distasonis increased beneficial commensal bacteria, significantly improved neurological deficits, pathological damages and BBB disruption, as well as reduced the level of serum uric acid in HAS rats. We further demonstrated that P. distasonis treatment decreased ROS level and increased SOD2 level, thereby reducing oxidative stress. Meanwhile, P. distasonis effectively inhibited NF-𝜿B signal pathway and reduced the production of inflammatory cytokines, including TNF-α and IL-1β, alleviating the inflammatory response. Notably, P. distasonis treatment increased the levels of vascular density markers including cluster of differentiation 31 (CD31) and alpha-smooth muscle actin (α-SMA), ameliorating vascular damage in HAS rats.</p><p><strong>Conclusions: </strong>Together, these findings highlighted the important role of P. distasonis in the pathogenesis of HAS, and its mechanism was involved in the regulation of gut microbiota-gut-brain axis, which implied a novel strategy against HAS.</p>\",\"PeriodicalId\":17458,\"journal\":{\"name\":\"Journal of Translational Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2024-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11539330/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12967-024-05800-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12967-024-05800-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:高尿酸血症被认为是急性缺血性卒中(AIS)的独立危险因素,一些AIS患者伴有血清尿酸升高。最近的研究强调了肠道微生物群在高尿酸血症和 AIS 中的重要作用,但关于肠道微生物群与伴有高尿酸血症(HAS)的 AIS 发病机制之间关系的现有数据很少。对患有高尿酸血症的雄性大鼠进行大脑中动脉闭塞(MCAO)以建立 HAS 模型,然后用 Parabacteroides distasonis 治疗。随后,对其神经功能缺损、病理损伤和血脑屏障破坏情况进行了评估。此外,还测定了 ROS、炎症细胞因子、NF-𝜿B 通路相关蛋白和血管密度标志物的水平:结果:HAS 患者与非 HAS 患者的肠道微生物群组成存在明显差异,与非 HAS 患者相比,HAS 患者体内 Parabacteroides 的丰度明显降低。动物实验表明,补充 distasonis 增加了有益共生菌,明显改善了 HAS 大鼠的神经功能缺损、病理损伤和 BBB 破坏,并降低了血清尿酸水平。我们进一步证实,P. distasonis 能降低 ROS 水平,提高 SOD2 水平,从而减轻氧化应激。同时,P. distasonis 能有效抑制 NF-𝜿B 信号通路,减少 TNF-α 和 IL-1β 等炎症细胞因子的产生,从而减轻炎症反应。值得注意的是,P. distasonis 治疗可提高血管密度标志物的水平,包括分化簇 31(CD31)和α-平滑肌肌动蛋白(α-SMA),从而改善 HAS 大鼠的血管损伤:综上所述,这些研究结果突出了远端孢子菌在 HAS 发病机制中的重要作用,其机制参与了肠道微生物群-肠-脑轴的调控,这意味着一种新型的 HAS 防治策略。
Gut commensal Parabacteroides distasonis exerts neuroprotective effects in acute ischemic stroke with hyperuricemia via regulating gut microbiota-gut-brain axis.
Background: Hyperuricemia is considered as an independent risk factor for acute ischemic stroke (AIS), and some AIS patients are accompanied by an increase in serum uric acid. Recent studies have highlighted the important role of gut microbiota in both hyperuricemia and AIS, but there is little available data on the relationship between gut microbiota and the pathogenesis of AIS with hyperuricemia (HAS).
Methods: Here we profiled the gut microbiota composition in 63 HAS patients and 269 non-HAS patients through 16s rRNA sequencing. Male rat with hyperuricemia were subjected to middle cerebral artery occlusion (MCAO) to establish HAS model and were then treated with Parabacteroides distasonis. Subsequently, the neurological deficit, pathological damages and blood-brain barrier disruption were evaluated. Moreover, the levels of ROS, inflammatory cytokines, NF-𝜿B pathway related protein, and vascular density markers were determined.
Results: There were significant differences of gut microbiota composition between HAS patients and non-HAS patients, and a significant decrease in the abundance of Parabacteroides in HAS patients compared to non-HAS patients. Animal experiments showed that supplementation with P. distasonis increased beneficial commensal bacteria, significantly improved neurological deficits, pathological damages and BBB disruption, as well as reduced the level of serum uric acid in HAS rats. We further demonstrated that P. distasonis treatment decreased ROS level and increased SOD2 level, thereby reducing oxidative stress. Meanwhile, P. distasonis effectively inhibited NF-𝜿B signal pathway and reduced the production of inflammatory cytokines, including TNF-α and IL-1β, alleviating the inflammatory response. Notably, P. distasonis treatment increased the levels of vascular density markers including cluster of differentiation 31 (CD31) and alpha-smooth muscle actin (α-SMA), ameliorating vascular damage in HAS rats.
Conclusions: Together, these findings highlighted the important role of P. distasonis in the pathogenesis of HAS, and its mechanism was involved in the regulation of gut microbiota-gut-brain axis, which implied a novel strategy against HAS.
期刊介绍:
The Journal of Translational Medicine is an open-access journal that publishes articles focusing on information derived from human experimentation to enhance communication between basic and clinical science. It covers all areas of translational medicine.